首页> 外文期刊>Oncogene >RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors
【24h】

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

机译:基于RNAi的人类激酶组筛选可识别Akt协同激酶:一种设计有效的多靶点激酶抑制剂的新方法

获取原文
           

摘要

Tumors comprise genetically heterogeneous cell populations, whose growth and survival depend on multiple signaling pathways. This has spurred the development of multitargeted therapies, including small molecules that can inhibit multiple kinases. A major challenge in designing such molecules is to determine which kinases to inhibit in each cancer to maximize efficacy and therapeutic index. We describe an approach to this problem implementing RNA interference technology. In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. siRNAs targeting casein kinase I gamma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-mediated cell killing, and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation. Small molecules targeting CSNK1G3 and/or IPMK in addition to Akt may thus exhibit increased efficacy and have the potential for improved therapeutic index.
机译:肿瘤包括遗传异质性细胞群,其生长和存活取决于多种信号通路。这刺激了多靶点疗法的发展,包括可以抑制多种激酶的小分子。设计此类分子的主要挑战是确定每种癌症中抑制哪些激酶以最大化疗效和治疗指数。我们描述了一种解决此问题的方法,该方法实现了RNA干扰技术。为了鉴定Akt协同激酶,我们筛选了一个激酶导向的小干扰RNA(siRNA)库,用于在Akt抑制剂A-443654存在的情况下增强癌细胞杀伤力。靶向酪蛋白激酶Iγ3(CSNK1G3)或肌醇多磷酸多激酶(IPMK)的siRNA显着增强了A-443654介导的细胞杀伤,并导致Akt Ser-473和核糖体蛋白S6磷酸化的降低。因此,除Akt外,靶向CSNK1G3和/或IPMK的小分子可能显示出更高的功效,并具有改善治疗指数的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号